Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets are indicated for: PROTONIX is a proton pump inhibitor (PPI) indicated for the following: • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) • Maintenance of Healing of Erosive Esophagitis ( 1.2 ) • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome… FDA label
Pantoprazole · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Pantoprazole 40 mg |
| Name | Type | Description |
|---|---|---|
| Pantoprazole | DRUG | Symptom Assessment after treatment with Pantoprozole 40 mg |
Main Inclusion Criteria: * Written informed consent * Outpatients * History of GERD-related symptoms for at least 6 months prior to study inclusion * Endoscopically confirmed erosive GERD or non-erosive GERD Main Exclusion Criteria: * Acute peptic ulcer and/or ulcer complications * PPIs during la...
Top 1 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | PHAT | 2 | PHASE3 | Vonoprazan |
Pantoprazole is used to treat gastroesophageal reflux disease (GERD) and gastroesophageal reflux, and it has also been studied in patients with chronic acid peptic complaints including peptic ulcers. It is a small molecule developed by Takeda Pharmaceutical Company Limited for gastrointestinal conditions.
Pantoprazole targets ATP4A and ATP4B. It acts as an inhibitor of these targets, which are components of the gastric proton pump involved in acid secretion. This mechanism underlies its use in acid-related gastrointestinal conditions such as GERD.
Pantoprazole is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the company associated with the clinical development program for pantoprazole in gastroesophageal reflux disease and related acid peptic conditions.
Pantoprazole has been studied in Phase 3 clinical development for GERD and related gastrointestinal indications. The Phase 3 trials listed for pantoprazole are all completed, and no trials are currently active. It is an investigational asset in the context of this development program.
Pantoprazole has been evaluated in completed Phase 3 trials including NCT00336219 in erosive and endoscopic-negative GERD, NCT00312806 in acid reflux disease, NCT00261300 in chronic acid peptic complaints, and NCT00163306 in acid reflux symptoms. These trials enrolled adults and were conducted across multiple countries.
The pantoprazole clinical trials listed enrolled a total of 2100 patients across four completed Phase 3 studies. Enrollment ranged from 100 patients in the long-term chronic acid peptic complaints trial to 2000 patients in the acid reflux disease trial.